MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.annonc.2020.06.007

Медицинская библиотека · Annals of oncology : official journal of the European Society for Medical Oncology · 2020

COVID-19 in patients with lung cancer.

Luo J, Rizvi H, Preeshagul I R, Egger J V, Hoyos D, Bandlamudi C, McCarthy C G, Falcon C J, Schoenfeld A J, Arbour K C, Chaft J E, Daly R M, Drilon A, Eng J, Iqbal A, Lai W V, Li B T, Lito P, Namakydoust A, Ng K, Offin M, Paik P K, Riely G J, Rudin C M, Yu H A, Zauderer M G, Donoghue M T A, Łuksza M, Greenbaum B D, Kris M G, Hellmann M D

СтатьяПоддержка NIH: внешняя программаПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

BACKGROUND

Patients with lung cancers may have disproportionately severe coronavirus disease 2019 (COVID-19) outcomes. Understanding the patient-specific and cancer-specific features that impact the severity of COVID-19 may inform optimal cancer care during this pandemic.

PATIENTS AND

METHODS

We examined consecutive patients with lung cancer and confirmed diagnosis of COVID-19 (n = 102) at a single center from 12 March 2020 to 6 May 2020. Thresholds of severity were defined a priori as hospitalization, intensive care unit/intubation/do not intubate ([ICU/intubation/DNI] a composite metric of severe disease), or death. Recovery was defined as >14 days from COVID-19 test and >3 days since symptom resolution. Human leukocyte antigen (HLA) alleles were inferred from MSK-IMPACT (n = 46) and compared with controls with lung cancer and no known non-COVID-19 (n = 5166).

RESULTS

COVID-19 was severe in patients with lung cancer (62% hospitalized, 25% died). Although severe, COVID-19 accounted for a minority of overall lung cancer deaths during the pandemic (11% overall). Determinants of COVID-19 severity were largely patient-specific features, including smoking status and chronic obstructive pulmonary disease [odds ratio for severe COVID-19 2.9, 95% confidence interval 1.07-9.44 comparing the median (23.5 pack-years) to never-smoker and 3.87, 95% confidence interval 1.35-9.68, respectively]. Cancer-specific features, including prior thoracic surgery/radiation and recent systemic therapies did not impact severity. Human leukocyte antigen supertypes were generally similar in mild or severe cases of COVID-19 compared with non-COVID-19 controls. Most patients recovered from COVID-19, including 25% patients initially requiring intubation. Among hospitalized patients, hydroxychloroquine did not improve COVID-19 outcomes.

CONCLUSION

COVID-19 is associated with high burden of severity in patients with lung cancer. Patient-specific features, rather than cancer-specific features or treatments, are the greatest determinants of severity.

Для цитирования: Luo J, Rizvi H, Preeshagul I R, Egger J V, Hoyos D, Bandlamudi C, McCarthy C G, Falcon C J, Schoenfeld A J, Arbour K C, Chaft J E, Daly R M, Drilon A, Eng J, Iqbal A, Lai W V, Li B T, Lito P, Namakydoust A, Ng K, Offin M, Paik P K, Riely G J, Rudin C M, Yu H A, Zauderer M G, Donoghue M T A, Łuksza M, Greenbaum B D, Kris M G, Hellmann M D. COVID-19 in patients with lung cancer.. Annals of oncology : official journal of the European Society for Medical Oncology. 2020. DOI: 10.1016/j.annonc.2020.06.007.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.